Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 164

1.

Targeting von Hippel-Lindau pathway in renal cell carcinoma.

Patel PH, Chadalavada RS, Chaganti RS, Motzer RJ.

Clin Cancer Res. 2006 Dec 15;12(24):7215-20. Review.

PMID:
17189392
[PubMed - indexed for MEDLINE]
Free Article
2.

Sunitinib, sorafenib and mTOR inhibitors in renal cancer.

Radulovic S, Bjelogrlic SK.

J BUON. 2007 Sep;12 Suppl 1:S151-62. Review.

PMID:
17935273
[PubMed - indexed for MEDLINE]
3.

[Molecular basis of targeted therapy in metastatic renal cancer].

Moch H.

Pathologe. 2008 Nov;29 Suppl 2:184-6. doi: 10.1007/s00292-008-1035-x. Review. German.

PMID:
18751979
[PubMed - indexed for MEDLINE]
4.

Targeted therapy for metastatic renal cell carcinoma.

Motzer RJ, Bukowski RM.

J Clin Oncol. 2006 Dec 10;24(35):5601-8. Review.

PMID:
17158546
[PubMed - indexed for MEDLINE]
5.

Renal-cell carcinoma--molecular pathways and therapies.

Brugarolas J.

N Engl J Med. 2007 Jan 11;356(2):185-7. No abstract available.

PMID:
17215538
[PubMed - indexed for MEDLINE]
6.

Molecular biology of renal cell carcinoma.

Mellado B, Gascón P.

Clin Transl Oncol. 2006 Oct;8(10):706-10. Review.

PMID:
17074668
[PubMed - indexed for MEDLINE]
7.

Recent advances in molecular targeted therapy for metastatic renal cell carcinoma.

Mizutani Y.

Int J Urol. 2009 May;16(5):444-8. doi: 10.1111/j.1442-2042.2009.02277.x. Epub 2009 Mar 3. Review.

PMID:
19298634
[PubMed - indexed for MEDLINE]
8.

Signaling inhibitors in metastatic renal cell carcinoma.

Escudier B.

Cancer J. 2008 Sep-Oct;14(5):325-9. doi: 10.1097/PPO.0b013e3181867605.

PMID:
18836338
[PubMed - indexed for MEDLINE]
9.

Progress in the management of advanced renal cell carcinoma (RCC).

Tong TQ, Rohde D, Peter S.

Aktuelle Urol. 2010 Jan;41 Suppl 1:S57-60. doi: 10.1055/s-0030-1247237. Epub 2010 Jan 21. Review.

PMID:
20094957
[PubMed - indexed for MEDLINE]
10.

[Molecular targeted therapy for renal cell carcinoma].

Kakehi Y.

Rinsho Ketsueki. 2008 Aug;49(8):622-5. Review. Japanese. No abstract available.

PMID:
18800611
[PubMed - indexed for MEDLINE]
11.

VEGF-targeted therapy in renal cell carcinoma: active drugs and active choices.

Rini BI.

Curr Oncol Rep. 2006 Mar;8(2):85-9. Review.

PMID:
16507216
[PubMed - indexed for MEDLINE]
12.

Blockade of the vascular endothelial growth factor-receptor 2 pathway inhibits the growth of human renal cell carcinoma, RBM1-IT4, in the kidney but not in the bone of nude mice.

Karashima T, Inoue K, Fukata S, Iiyama T, Kurabayashi A, Kawada C, Shuin T.

Int J Oncol. 2007 Apr;30(4):937-45.

PMID:
17332933
[PubMed - indexed for MEDLINE]
13.

Opportunities and obstacles to combination targeted therapy in renal cell cancer.

Sosman JA, Puzanov I, Atkins MB.

Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):764s-769s. Review.

PMID:
17255307
[PubMed - indexed for MEDLINE]
Free Article
14.

von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma.

Choueiri TK, Vaziri SA, Jaeger E, Elson P, Wood L, Bhalla IP, Small EJ, Weinberg V, Sein N, Simko J, Golshayan AR, Sercia L, Zhou M, Waldman FM, Rini BI, Bukowski RM, Ganapathi R.

J Urol. 2008 Sep;180(3):860-5; discussion 865-6. doi: 10.1016/j.juro.2008.05.015. Epub 2008 Jul 17.

PMID:
18635227
[PubMed - indexed for MEDLINE]
15.

An update on the medical therapy of advanced metastatic renal cell carcinoma.

Kruck S, Merseburger AS, Gakis G, Kramer MW, Stenzl A, Kuczyk MA.

Scand J Urol Nephrol. 2008;42(6):501-6. doi: 10.1080/00365590802203983. Review.

PMID:
18615363
[PubMed - indexed for MEDLINE]
16.

Sorafenib and sunitinib: novel targeted therapies for renal cell cancer.

Grandinetti CA, Goldspiel BR.

Pharmacotherapy. 2007 Aug;27(8):1125-44. Review.

PMID:
17655513
[PubMed - indexed for MEDLINE]
17.

The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma.

Kaelin WG Jr.

Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):680s-684s. Review.

PMID:
17255293
[PubMed - indexed for MEDLINE]
Free Article
18.

Sorafenib: scientific rationales for single-agent and combination therapy in clear-cell renal cell carcinoma.

Gollob JA.

Clin Genitourin Cancer. 2005 Dec;4(3):167-74. Review.

PMID:
16425993
[PubMed - indexed for MEDLINE]
19.

Phase 2 studies of sunitinib and AG013736 in patients with cytokine-refractory renal cell carcinoma.

George DJ.

Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):753s-757s. Review.

PMID:
17255305
[PubMed - indexed for MEDLINE]
Free Article
20.

Targeting vascular endothelial growth factor in renal cell carcinoma.

Patel NS, Muneer A, Blick C, Arya M, Harris AL.

Tumour Biol. 2009;30(5-6):292-9. doi: 10.1159/000260241. Epub 2009 Nov 20. Review.

PMID:
19940550
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk